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globally. It is the leading cause of death in both developed and 
emerging economies [1]. In 2012, there were 14.1 million new cancer 
cases, 8.2 million cancer mortalities, and 32.6 million people living 
with cancer globally [2]. Cancers are caused by a complex interplay 
between genetic predisposition and environment. Family and 
twin studies have shown the estimated effects of heritability of the 
colorectal cancer (35%) [3], breast cancer (25-30%) [3-5], prostate 
cancer (42-58%) [3,6], and lung cancer (25-26%) [3,7].
The protein tyrosine phosphatase, receptor type, N polypeptide 
2 (PTPRN2) gene (also known as IAR, ICAAR, PTPRP, IA-2beta, 
R-PTP-N2) is located at 7q36 [8,9]. The PTPRN2 is expressed 
primarily in human brain and pancreas and in mouse brain, pancreas, 
and insulinoma cell lines [10,11]. One methylation study found that 
PTPRN2 showed highly significant hypermethylation in squamous 
cell lung cancer tissue [12]. Another gene expression profile study 
suggested that PTPRN2 was associated with metastatic prostate 
cancer [13]. A recent study reported that PTPRN2 was expressed 
predominantly in endocrine and neuronal cells, where it might 
function in exocytosis and suggested as a novel candidate biomarker 
and therapeutic target in breast cancer [14].
However, no study has focused on the associations of genetic 
variants of PTPRN2 gene with age at onset (AAO) of cancer. 
Furthermore, Bayesian methods have become increasingly popular 
in many areas of scientific research including genetic association 
studies, which may have some advantages in flexibility, and 
incorporating information from previous studies and dealing with 
sparse-data [15-17]. In this study, we explored the associations of 
220 SNPs in the PTPRN2 gene with AAO of cancer using a Bayesian 
survival analysis in a Caucasian sample.
Subjects and Methods
The Marshfield sample
The Marshfield sample is from the publicly available data in 
A Genome-Wide Association Study on Cataract and HDL in the 
Abstract
Background: The protein tyrosine phosphatase, receptor type, N 
polypeptide 2 (PTPRN2) gene may play a role in cancer; however, 
no study has focused on the associations of genetic variants within 
the PTPRN2 gene with age at onset (AAO) of cancer.
Methods: This study examined 220 single nucleotide 
polymorphisms (SNPs) within the PTPRN2 gene in the Marshfield 
sample with 716 cancer cases (any diagnosed cancer, excluding 
minor skin cancer) and 2,848 non-cancer controls. Multiple logistic 
regression model and linear regression model in PLINK software 
were used to examine the association of each SNP with the risk 
of cancer and AAO, respectively. For survival analysis of AAO, 
both classic Cox regression and Bayesian survival analysis using 
the Cox proportional hazards model in SAS v. 9.4 were applied to 
detect the association of each SNP with AAO. The hazards ratios 
(HRs) with 95% confidence intervals (CIs) were estimated.
Results: Single marker analysis identified 10 SNPs associated 
with the risk of cancer and 9 SNPs associated with AAO (p < 0.05). 
SNP rs7783909 revealed the strongest association with cancer 
(p = 6.52x10-3); while the best signal for AAO was rs4909140 (p 
= 6.18x10-4), which was also associated with risk of cancer (p = 
0.0157). Classic Cox regression model showed that 11 SNPs were 
associated with AAO (top SNP rs4909140 with HR = 1.38, 95%CI 
= 1.11-1.71, p = 3.3x10-3). Bayesian Cox regression model showed 
similar results to those using the classic Cox regression (top SNP 
rs4909140 with HR = 1.39, 95%CI = 1.1-1.69).
Conclusions: This study provides evidence of several genetic 
variants within the PTPRN2 gene influencing the risk of cancer 
and AAO, and will serve as a resource for replication in other 
populations.
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Introduction
Cancer continues to remain a significant public health issue 
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Personalized Medicine Research Project Cohort - Study Accession: 
phs000170.v1.p1 (dbGaP). The details about these subjects were 
described elsewhere [18,19]. Cancer cases were defined as any 
diagnosed cancer excluding minor skin cancer; while AAO cancer 
was defined by date of the earliest cancer diagnosis in the registry. 
Social factors used in this study were age, gender, alcohol use in 
the past month (yes or no), and smoking status (never smoking, 
current smoking and past smoking). Obesity was determined as a 
body mass index (BMI) ≥ 30. Genotyping data using the ILLUMINA 
Human660W-Quad_v1_A are available for 3564 Caucasian 
individuals (716 cancer cases and 2848 controls). Within the PTPRN2 
gene, 220 SNPs were available and therefore included in the analysis.
Statistical methods
Linear and logistic regression models in PLINK software: 
The categorical variables were presented as frequencies and 
percentages. The continuous variables were reported as the means 
± standard deviation. Quality-control and association analyses 
were implemented using PLINK V1.07 [20]. First, Hardy-Weinberg 
equilibrium (HWE) was tested for all the SNPs using the controls; 
then, minor allele frequency (MAF) was determined for each 
SNP. Multiple logistic regression analysis of each SNP with risk 
of cancer as a binary trait, adjusted for sex, age*age, alcohol use, 
smoking status, and obesity, was performed using PLINK; while 
the asymptotic p-values were observed and the odds ratio (OR) and 
95% confident interval (CI) were estimated. Furthermore, AAO 
values were firstly log transformed, then multiple linear regression 
analysis of each SNP with log transformed AAO of cancer, adjust for 
sex, alcohol use, smoking status, and obesity was performed; while 
the asymptotic p-values were observed and the regression coefficient 
(β) and 95% CI were estimated. To control for type I errors arising 
from multiple hypothesis testing, a false discovery rate (FDR) was 
defined in Benjamini and Hochberg [21] as the expected proportion 
of false discoveries. In addition, empirical p-values were generated by 
100,000 permutation tests using Max (T) permutation procedure. In 
this procedure, pointwise estimate of an individual SNP’s significance 
(empirical pointwise p-values) was calculated.
Cox proportional hazards models in PROC PHREG: The 
proportional hazards model or Cox regression model, is widely used 
in the analysis of time-to-event data to explain the effect of explanatory 
variables on hazard rates. The PHREG procedure fits the Cox model 
by maximizing the partial likelihood function; this eliminates the 
unknown baseline hazard and accounts for censored survival times. 
In the Bayesian approach, the partial likelihood function is used as 
the likelihood function in the posterior distribution [22]. In the non-
Bayesian analysis, the Akaike information criterion (AIC) was used 
as a measure of goodness of model fit that balances model fit against 
model simplicity [23,24]. Bayesian Cox regression can be requested 
by using the BAYES statement in the PHREG procedure. A Markov 
chain Monte Carlo (MCMC) method by Gibbs sampling was used 
to simulate samples from the posterior distribution. In a Bayesian 
analysis, a Gibbs chain of samples from the posterior distribution 
was generated for the model parameters. Summary statistics (mean, 
standard deviation, quartiles, the highest posterior density (HPD) and 
credible intervals, correlation matrix) and convergence diagnostics 
(Geweke; the effective sample size; and Monte Carlo standard errors) 
were computed for each parameter, as well as the correlation matrix 
and the covariance matrix of the posterior sample. Trace plots, 
posterior density plots, and autocorrelation function plots were 
created for each parameter [17]. The hazards ratios (HRs) with 95% 
CIs were estimated.
For the present study of the AAO, the normal prior was chosen 
for the coefficients. In Bayesian analysis, a deviance information 
criterion (DIC) is available for model comparison instead of AIC. 
DIC is a hierarchical modeling generalization of the AIC; while DIC 
is intended as a generalization of AIC [25]. The following program 
showed one SNP rs4909140, sex, alcohol use, smoking status, and 
obesity with the AAO of cancer. The rs4909140 has 3 genotypes 
- G_G, G_T and T_T, respectively; while the T_T genotype was 
considered as the reference.
proc phreg data= aao;
class sex(ref ="1") obesity (ref ="1") alcohol(ref ="1") smoking(ref 
="1") rs4909140 (ref = "T_T") ;
model canceraao*statuscan(0) = sex obesity alcohol smoking 
rs4909140/risklimits;
bayes seed =1000 nbi =10000 nmc =100000 thin =10 seed =1000 
cprior=normal(var =1e6) outpost = out plots = density;
hazardratio rs4909140;
run;
Descriptive statistics and Cox regression analyses were conducted 
with SAS v.9.4 (SAS Institute, Cary, NC, USA).
Results
Genotype quality control and descriptive statistics
We removed 1 SNP with HWE p < 10-4. All other 219 SNPs 
were in HWE with MAF > 1% in the controls. The demographic 
characteristics of the subjects in the study are presented in Table 
1. There were slightly more females than males in both cases and 
controls. The age ranged from 46 to 90 years and AAO of cancer 
ranged from 23 to 90 years.
Multiple linear and logistic regression analyses using PLINK
Using a single marker analysis, we identified 10 SNPs associated 
with the risk of cancer and 9 SNPs associated with AAO (p < 0.05) in 
the Marshfield sample (Table 2). SNP rs7783909 revealed the strongest 
association with cancer (p = 6.52x10-3); while the best signal for AAO 
was rs4909140 (p = 6.18x10-4), which was also associated with risk of 
cancer (p = 0.0157). For the 10 SNPs associated with risk of cancer, 
the FDR was 90%; while the FDR for the two AAO mostly associated 
SNPs (rs4409140 and rs1670340) were 21% and 39%, respectively. 
Furthermore, we conducted a permutation test in PLINK and found 
that all the cancer and or AAO associated SNPs had empirical point 
wise p-values p < 0.05 using a permutation test (Table 2).
Classic and Bayesian Cox regression analyses using PROC 
PHREG
Classic Cox regression model showed that 11 SNPs were associated 
with AAO (top SNP rs4909140 with HR=1.38, 95%CI = 1.11-1.71, p 
= 3.3x10-3). The HRs based on the Bayesian survival analyses revealed 
similar results to those using the non-Bayesian analyses results (Table 
3). The DIC for the 11 SNPs in the Bayesian analyses were similar to 




  Males 1135(40%) 340(47%)
  Females 1713(60%) 376(53%)
Obesity, N (%)
  No 1700(60%) 422(59%)
  Yes 1148(40%) 294(41%)
Alcohol, N (%)
  No 1060(37%) 288(40%)
  Yes 1783(63%) 425(60%)
Smoking, N (%)
  Never 1487(52%) 327(46%)
  Current 254(9%) 54(7%)
  Past 1104(39%) 331(47%)
Age, years
  Mean ± SD  65.1 ± 11.3 71.1 ± 10.3
  Range 46-90 46-90
Age at onset, years
  Mean  ±  SD  - 64.2 ± 12.8
  Range - 23-90
Wang et al. Int J Clin Biostat Biom 2015, 1:1 • Page 3 of 6 •ISSN: 2469-5831
those of AIC using classic Cox model.
The trace plot, posterior density plot, and autocorrelation function 
plot based on Bayesian analysis (Figure 1) indicated that the Markov 
chain had stabilized with good mixing for rs4909140. The posterior 
density plot, which estimates the posterior marginal distributions 
for the 7 regression coefficients showed a smooth, unimodal shape 
for the posterior marginal distribution (Figure 2). Table 4 shows the 
posterior summary of rs4909140 with HR = 1.39, 95% CI = 1.1-1.69.
Discussion
In this study, we identified 10 SNPs associated with the risk of 
cancer and 9 SNPs with AAO using the PLINK software and 11 SNPs 
Table 2: SNPs within the PTPRN2 gene associated with risk and age at onset of cancer using PLINK (p < 0.05)
SNP Positiona Alleleb MAFc HWEd OR-Cancere p-Cancerf EMPg β-AAOh p-AAOi EMPj
rs7783909 157287177 A 0.15 0.413 1.42(1.1-1.83) 6.52E-03 4.0E-03 -0.017 0.0713 0.0739
rs4909140 157721662 G 0.46 0.727 1.16(1.03-1.31) 1.57E-02 1.1E-02 -0.017 6.18E-04 4.0E-03
rs10244830 157674626 T 0.35 0.318 0.84(0.73-0.97) 1.81E-02 1.4E-02  0.002 0.7115 0.699
rs7795387 157764272 G 0.22 0.409 0.74(0.57-0.96) 2.23E-02 2.2E-02  0.002 0.844 0.856
rs6970487 157712908 G 0.42 0.561 0.86(0.76-0.98) 2.55E-02 2.8E-02  0.01 0.0653 0.0579
rs4595081 157700684 T 0.42 0.475 0.86(0.76-0.98) 2.69E-02 2.9E-02  0.01 0.065 0.058
rs6944416 157708321 G 0.42 0.623 0.86(0.76-0.98) 2.78E-02 3.0E-02  0.01 0.064 0.06
rs17837789 157128182 G 0.15 0.186 0.63(0.41-0.96) 3.29E-02 2.8E-02 -0.027 0.159 0.155
rs920023 157427075 G 0.24 0.768 0.8(0.65-0.99) 4.03E-02 3.9E-02  0.016 0.0751 0.0739
rs4909289 157647665 A 0.26 0.82 0.82(0.68-0.99) 4.85E-02 4.3E-02  0.003 0.699 0.687
rs1670340 157963783 C 0.49 0.385 0.97(0.86-1.1) 0.654 0.687 -0.016 1.69E-03 2.0E-03
rs1630862 157961357 G 0.45 0.965 0.97(0.86-1.09) 0.588 0.598 -0.013 1.17E-02 0.012
rs11760246 157523437 T 0.37 0.016 1.04(0.91-1.19) 0.529 0.54  0.013 1.81E-02 0.025
rs1268391 157111665 C 0.32 0.841 0.96(0.83-1.12) 0.606 0.62 -0.015 2.16E-02 0.023
rs7777448 157724510 A 0.39 0.99 0.98(0.86-1.12) 0.736 0.712 -0.013 2.38E-02 0.034
rs3752374 157581981 G 0.05 0.662 1.73(0.73-4.11) 0.239 0.155 -0.07 3.29E-02 0.04
rs10949670 157388704 T 0.39 0.142 1.0(0.88-1.14) 0.956 0.95  0.011 3.95E-02 0.043
rs12698149 rs12698149 T 0.39 0.238 1.05(0.92-1.19) 0.494 0.504  0.011 3.95E-02 0.045
a Physical position(bp); b Minor allele; c Minor allele frequency; d Hardy-Weinberg equilibrium test p-value; e Odds ratio for the risk of cancer based on logistic regression 
using PLINK; f p-value for the risk of cancer based on logistic regression; g empirical p-value for the risk of cancer generated by 100,000 permutation tests using Max 
(T) permutation procedure implemented in PLINK;  h Regression coefficient for AAO of cancer based on linear regression using PLINK; i p-value for AAO of cancer 
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Figure 1:  Trace plot, autocorrelation function plot, and posterior density plot for rs4909140.
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revealed associations with AAO using Cox survival model in SAS. 
Bayesian Cox regression model revealed similar findings to those 
using the classic Cox regression. To our knowledge, this is the first 
candidate gene study to provide evidence of several genetic variants 
within the PTPRN2 gene associated with the risk of cancer and AAO.
Previous studies have showed that PTPRN2 is an autoantigen 
for type 1 diabetes which is an insulin-dependent diabetes mellitus 
and autoimmune disease; while PTPRN2 is reactive with type 1 
diabetes patient sera and is likely to be an islet cell antigen useful in 
the preclinical screening of individuals for the risk of type 1 diabetes 
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Figure 2: The posterior density plots for the 7 regression coefficients.
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[10,26-28]. Animal model studies revealed that this gene may be 
functioned in the regulation of insulin secretion [11,29-32]. Recently, 
another study suggested that PTPRN2 (IA-2beta) is one of the genes 
potentially relevant to insulin and neurotransmitter release [33]. 
Furthermore, several studies have reported that the PTPRN2 gene 
may be involved in squamous cell lung cancer tissue [12], metastatic 
prostate cancer [13] and breast cancer [14]. However, the mechanism 
is not clear. It has been hypothesized that recurrent or clonal somatic 
mutation underlies the initiation of autoimmune disease such as 
type 1 diabetes [34]; while many cancers elicit antibodies that are 
also found in autoimmune diseases [35]. Therefore, PTPRN2 may be 
one of the mechanisms linking autoimmune diseases to cancers. In 
addition, insulin, insulinlike growth factor 1, and insulinlike growth 
factor 2 signaling through the insulin receptor and the insulinlike 
growth factor 1 receptor could induce tumorigenesis, accounting to 
some extent for the link between diabetes, metabolic syndrome and 
cancers [36,37].
However, no association study of genetic polymorphisms 
within the PTPRN2 gene with the risk of cancer and AAO has been 
conducted. The present study provides the first evidence of several 
genetic variants within the PTPRN2 gene is associated with the risk 
and AAO of cancer using multiple logistic and linear regression 
models. We identified the main effects and permutation p-values 
for single SNPs. Furthermore, we conducted Bayesian survival 
analysis of genetic variants with AAO. Bayesian methods may have 
some advantages in flexibility and incorporating information from 
previous studies. For example, Bayesian method may provide an 
alternative approach to assessing associations that alleviates the 
limitations of p-values at the cost of some additional modelling. It 
has recently made great inroads into many areas of science, including 
the assessment of associations between genetic variants and disease 
or related phenotypes [15]. We also realized some limitations in this 
study. First, the definition of cancer status in the Marshfield sample 
was broad (including any diagnosed cancer omitting minor skin 
cancer). It would be more informative to investigate the association 
of PTPRN2 gene with particular types of cancer. Furthermore, our 
current findings might be subject to type I error and findings need to 
be replicated in additional samples.
Conclusion
This study provides evidence of several genetic variants within 
the PTPRN2 gene influencing the risk and AAO of cancer. Future 
functional study of this gene may help to better characterize the 
genetic architecture of cancers.
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